Listed

Ligand Pharmaceuticals Inc

LGNDNasdaqCIK 886163HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$63.7m, Q2 FY2026
Operating income$8.6m, Q2 FY2026
Net income$48.5m, Q2 FY2026
Ligand Pharmaceuticals Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m32.9Revenue, Q3 FY2023, three months to 2023-09-30$32.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure28.1Revenue, Q4 FY2023, three months to 2023-12-31$28.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure31.0Revenue, Q1 FY2024, three months to 2024-03-31$31.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure41.5Revenue, Q2 FY2024, three months to 2024-06-30$41.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure51.8Revenue, Q3 FY2024, three months to 2024-09-30$51.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure42.8Revenue, Q4 FY2024, three months to 2024-12-31$42.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure45.3Revenue, Q1 FY2025, three months to 2025-03-31$45.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure47.6Revenue, Q2 FY2025, three months to 2025-06-30$47.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure115Revenue, Q3 FY2025, three months to 2025-09-30$115.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure59.7Revenue, Q4 FY2025, three months to 2025-12-31$59.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure51.7Revenue, Q1 FY2026, three months to 2026-03-31$51.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure63.7Revenue, Q2 FY2026, three months to 2026-06-30$63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m5.5Research and development, Q3 FY2023, three months to 2023-09-30$5.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure5.5Research and development, Q4 FY2023, three months to 2023-12-31$5.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure6.0Research and development, Q1 FY2024, three months to 2024-03-31$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure5.4Research and development, Q2 FY2024, three months to 2024-06-30$5.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure5.7Research and development, Q3 FY2024, three months to 2024-09-30$5.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure4.4Research and development, Q4 FY2024, three months to 2024-12-31$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure50.1Research and development, Q1 FY2025, three months to 2025-03-31$50.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure6.6Research and development, Q2 FY2025, three months to 2025-06-30$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure21.0Research and development, Q3 FY2025, three months to 2025-09-30$21.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure3.5Research and development, Q4 FY2025, three months to 2025-12-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure2.1Research and development, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure14.7Research and development, Q2 FY2026, three months to 2026-06-30$14.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Operating income$m3.1Operating income, Q3 FY2023, three months to 2023-09-30$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure(3.4)Operating income, Q4 FY2023, three months to 2023-12-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure3.0Operating income, Q1 FY2024, three months to 2024-03-31$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure(19.1)Operating income, Q2 FY2024, three months to 2024-06-30−$19.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure3.1Operating income, Q3 FY2024, three months to 2024-09-30$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(9.6)Operating income, Q4 FY2024, three months to 2024-12-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(36.2)Operating income, Q1 FY2025, three months to 2025-03-31−$36.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure8.4Operating income, Q2 FY2025, three months to 2025-06-30$8.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure54.9Operating income, Q3 FY2025, three months to 2025-09-30$54.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure13.8Operating income, Q4 FY2025, three months to 2025-12-31$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure17.4Operating income, Q1 FY2026, three months to 2026-03-31$17.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure8.6Operating income, Q2 FY2026, three months to 2026-06-30$8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$1.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure0.1Interest expense, Q4 FY2023, three months to 2023-12-31$131.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-02-29, accession 0000886163-24-000009. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2024, three months to 2024-03-31$141.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure1.3Interest expense, Q2 FY2024, three months to 2024-06-30$1.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure0.7Interest expense, Q3 FY2024, three months to 2024-09-30$741.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure0.9Interest expense, Q4 FY2024, three months to 2024-12-31$883.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure0.9Interest expense, Q1 FY2025, three months to 2025-03-31$867.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure1.2Interest expense, Q2 FY2025, three months to 2025-06-30$1.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure0.9Interest expense, Q3 FY2025, three months to 2025-09-30$910.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure1.8Interest expense, Q4 FY2025, three months to 2025-12-31$1.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure1.7Interest expense, Q1 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure1.7Interest expense, Q2 FY2026, three months to 2026-06-30$1.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Income tax$m(1.9)Income tax, Q3 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure(1.1)Income tax, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure27.3Income tax, Q1 FY2024, three months to 2024-03-31$27.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure(13.5)Income tax, Q2 FY2024, three months to 2024-06-30−$13.5m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure0.8Income tax, Q3 FY2024, three months to 2024-09-30$833.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(8.1)Income tax, Q4 FY2024, three months to 2024-12-31−$8.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(7.7)Income tax, Q1 FY2025, three months to 2025-03-31−$7.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure6.4Income tax, Q2 FY2025, three months to 2025-06-30$6.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure23.9Income tax, Q3 FY2025, three months to 2025-09-30$23.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure12.0Income tax, Q4 FY2025, three months to 2025-12-31$12.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(10.9)Income tax, Q1 FY2026, three months to 2026-03-31−$10.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure15.8Income tax, Q2 FY2026, three months to 2026-06-30$15.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Net income$m(10.3)Net income, Q3 FY2023, three months to 2023-09-30−$10.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure18.2Net income, Q4 FY2023, three months to 2023-12-31$18.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure86.1Net income, Q1 FY2024, three months to 2024-03-31$86.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(51.9)Net income, Q2 FY2024, three months to 2024-06-30−$51.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(7.2)Net income, Q3 FY2024, three months to 2024-09-30−$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure(31.1)Net income, Q4 FY2024, three months to 2024-12-31−$31.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(42.5)Net income, Q1 FY2025, three months to 2025-03-31−$42.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure4.8Net income, Q2 FY2025, three months to 2025-06-30$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure117Net income, Q3 FY2025, three months to 2025-09-30$117.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure44.8Net income, Q4 FY2025, three months to 2025-12-31$44.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(13.3)Net income, Q1 FY2026, three months to 2026-03-31−$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure48.5Net income, Q2 FY2026, three months to 2026-06-30$48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Diluted EPS$ per share(0.59)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figurenot reported4.75Diluted EPS, Q1 FY2024, three months to 2024-03-31$4.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure(2.88)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$2.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure(0.39)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported(2.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure0.24Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure5.68Diluted EPS, Q3 FY2025, three months to 2025-09-30$5.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported(0.67)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure2.22Diluted EPS, Q2 FY2026, three months to 2026-06-30$2.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Basic EPS$ per share(0.59)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figurenot reported4.86Basic EPS, Q1 FY2024, three months to 2024-03-31$4.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure(2.88)Basic EPS, Q2 FY2024, three months to 2024-06-30−$2.88 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure(0.39)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported(2.21)Basic EPS, Q1 FY2025, three months to 2025-03-31−$2.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure0.25Basic EPS, Q2 FY2025, three months to 2025-06-30$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure5.99Basic EPS, Q3 FY2025, three months to 2025-09-30$5.99 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figurenot reported(0.67)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure2.42Basic EPS, Q2 FY2026, three months to 2026-06-30$2.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure

Balance sheet

Cash and equivalents$1.01bn, Q2 FY2026
Long-term debt$1.13bn, Q2 FY2026
Shareholders' equity$967.5m, Q2 FY2026
Ligand Pharmaceuticals Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m19.3Cash and equivalents, Q3 FY2023, at 2023-09-30$19.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure23.0Cash and equivalents, FY2023, at 2023-12-31$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure50.1Cash and equivalents, Q1 FY2024, at 2024-03-31$50.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure18.1Cash and equivalents, Q2 FY2024, at 2024-06-30$18.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure63.6Cash and equivalents, Q3 FY2024, at 2024-09-30$63.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure72.3Cash and equivalents, FY2024, at 2024-12-31$72.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure48.0Cash and equivalents, Q1 FY2025, at 2025-03-31$48.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure67.7Cash and equivalents, Q2 FY2025, at 2025-06-30$67.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure139Cash and equivalents, Q3 FY2025, at 2025-09-30$139.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure175Cash and equivalents, FY2025, at 2025-12-31$174.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure115Cash and equivalents, Q1 FY2026, at 2026-03-31$115.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure1,007Cash and equivalents, Q2 FY2026, at 2026-06-30$1.01bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Current assets$m254Current assets, Q3 FY2023, at 2023-09-30$254.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure237Current assets, FY2023, at 2023-12-31$237.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure369Current assets, Q1 FY2024, at 2024-03-31$368.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure312Current assets, Q2 FY2024, at 2024-06-30$312.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure309Current assets, Q3 FY2024, at 2024-09-30$309.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure332Current assets, FY2024, at 2024-12-31$331.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure309Current assets, Q1 FY2025, at 2025-03-31$309.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure353Current assets, Q2 FY2025, at 2025-06-30$352.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure754Current assets, Q3 FY2025, at 2025-09-30$753.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure832Current assets, FY2025, at 2025-12-31$832.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure865Current assets, Q1 FY2026, at 2026-03-31$865.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure1,457Current assets, Q2 FY2026, at 2026-06-30$1.46bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Total assets$m769Total assets, Q3 FY2023, at 2023-09-30$769.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure787Total assets, FY2023, at 2023-12-31$787.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure914Total assets, Q1 FY2024, at 2024-03-31$913.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure866Total assets, Q2 FY2024, at 2024-06-30$866.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure955Total assets, Q3 FY2024, at 2024-09-30$954.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure942Total assets, FY2024, at 2024-12-31$941.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure905Total assets, Q1 FY2025, at 2025-03-31$905.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure949Total assets, Q2 FY2025, at 2025-06-30$948.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure1,477Total assets, Q3 FY2025, at 2025-09-30$1.48bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure1,561Total assets, FY2025, at 2025-12-31$1.56bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure1,532Total assets, Q1 FY2026, at 2026-03-31$1.53bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure2,186Total assets, Q2 FY2026, at 2026-06-30$2.19bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Current liabilities$m15.7Current liabilities, Q3 FY2023, at 2023-09-30$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure16.8Current liabilities, FY2023, at 2023-12-31$16.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure17.8Current liabilities, Q1 FY2024, at 2024-03-31$17.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure18.6Current liabilities, Q2 FY2024, at 2024-06-30$18.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure24.8Current liabilities, Q3 FY2024, at 2024-09-30$24.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure37.1Current liabilities, FY2024, at 2024-12-31$37.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure58.7Current liabilities, Q1 FY2025, at 2025-03-31$58.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure64.7Current liabilities, Q2 FY2025, at 2025-06-30$64.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure30.5Current liabilities, Q3 FY2025, at 2025-09-30$30.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure37.4Current liabilities, FY2025, at 2025-12-31$37.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure40.7Current liabilities, Q1 FY2026, at 2026-03-31$40.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure46.7Current liabilities, Q2 FY2026, at 2026-06-30$46.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Total liabilities$m101Total liabilities, Q3 FY2023, at 2023-09-30$101.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure86.3Total liabilities, FY2023, at 2023-12-31$86.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-28, accession 0000886163-25-000012.Report this figure107Total liabilities, Q1 FY2024, at 2024-03-31$107.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure91.2Total liabilities, Q2 FY2024, at 2024-06-30$91.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure114Total liabilities, Q3 FY2024, at 2024-09-30$113.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure111Total liabilities, FY2024, at 2024-12-31$111.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure110Total liabilities, Q1 FY2025, at 2025-03-31$109.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure120Total liabilities, Q2 FY2025, at 2025-06-30$120.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure527Total liabilities, Q3 FY2025, at 2025-09-30$526.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure543Total liabilities, FY2025, at 2025-12-31$543.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure535Total liabilities, Q1 FY2026, at 2026-03-31$534.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure1,218Total liabilities, Q2 FY2026, at 2026-06-30$1.22bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported1,127Long-term debt, Q2 FY2026, at 2026-06-30$1.13bn. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure
Shareholders' equity$m668Shareholders' equity, Q3 FY2023, at 2023-09-30$667.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure701Shareholders' equity, FY2023, at 2023-12-31$700.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-27, accession 0000886163-26-000006.Report this figure807Shareholders' equity, Q1 FY2024, at 2024-03-31$806.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure775Shareholders' equity, Q2 FY2024, at 2024-06-30$775.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure841Shareholders' equity, Q3 FY2024, at 2024-09-30$841.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure830Shareholders' equity, FY2024, at 2024-12-31$830.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure796Shareholders' equity, Q1 FY2025, at 2025-03-31$795.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure827Shareholders' equity, Q2 FY2025, at 2025-06-30$827.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure950Shareholders' equity, Q3 FY2025, at 2025-09-30$950.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure1,017Shareholders' equity, FY2025, at 2025-12-31$1.02bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure997Shareholders' equity, Q1 FY2026, at 2026-03-31$997.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure968Shareholders' equity, Q2 FY2026, at 2026-06-30$967.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure

Cash flow

Operating cash flow$24.0m, Q2 FY2026
Capital expenditure$26.0k, Q2 FY2026
Share repurchases$0, Q4 FY2025
Ligand Pharmaceuticals Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m7.6Operating cash flow, Q3 FY2023, three months to 2023-09-30$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-08, accession 0000886163-24-000078. Derived: 9-month figure less the 6-month figure.Report this figure8.1Operating cash flow, Q4 FY2023, three months to 2023-12-31$8.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure18.7Operating cash flow, Q1 FY2024, three months to 2024-03-31$18.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure13.3Operating cash flow, Q2 FY2024, three months to 2024-06-30$13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0000886163-25-000051. Derived: 6-month figure less the 3-month figure.Report this figure36.5Operating cash flow, Q3 FY2024, three months to 2024-09-30$36.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure28.5Operating cash flow, Q4 FY2024, three months to 2024-12-31$28.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(25.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$25.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure15.8Operating cash flow, Q2 FY2025, three months to 2025-06-30$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure13.1Operating cash flow, Q3 FY2025, three months to 2025-09-30$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure45.9Operating cash flow, Q4 FY2025, three months to 2025-12-31$45.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure48.7Operating cash flow, Q1 FY2026, three months to 2026-03-31$48.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure24.0Operating cash flow, Q2 FY2026, three months to 2026-06-30$24.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.5Capital expenditure, Q3 FY2023, three months to 2023-09-30$487.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-08, accession 0000886163-24-000078. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2023, three months to 2023-12-31$417.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$105.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure0.4Capital expenditure, Q2 FY2024, three months to 2024-06-30$408.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-08, accession 0000886163-25-000051. Derived: 6-month figure less the 3-month figure.Report this figure0.6Capital expenditure, Q3 FY2024, three months to 2024-09-30$596.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure0.7Capital expenditure, Q4 FY2024, three months to 2024-12-31$712.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2025, three months to 2025-03-31$214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$15.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$228.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0000886163-26-000044. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reported0.0Share repurchases, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported15.0Share repurchases, Q3 FY2025, three months to 2025-09-30$15.0m. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-11-07, accession 0000886163-25-000063. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-02-27, accession 0000886163-26-000006. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)21.84m, Q2 FY2026
Ligand Pharmaceuticals Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares17.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3017,132,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000886163-23-000086.Report this figure18.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3117,974,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000886163-24-000032.Report this figure17.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3017,730,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0000886163-24-000071.Report this figure17.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3017,380,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-08, accession 0000886163-24-000078.Report this figure18.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3118,122,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0000886163-25-000036.Report this figure18.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3018,028,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0000886163-25-000051.Report this figure18.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3018,419,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure19.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3119,191,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure19.9Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3019,926,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure20.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3020,629,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0000886163-25-000063.Report this figure19.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3119,883,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0000886163-26-000034.Report this figure21.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3021,837,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure

Shares outstanding: 19.94mShares outstanding, period not labelled, at 2026-08-0419,935,609 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-07, accession 0000886163-26-000044.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.